Resverlogix Corp. is a publicly traded biotechnology company (TSX:RVX) focused on developing novel therapies for unmet medical markets, primarily cardiovascular disease (CVD), cancer and fibrotic conditions. Our goal is to improve the quality and longevity of patient’s lives by becoming a leader in the research, development and commercialization of innovative products for these grievous diseases.

Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.